Treating adolescents for substance abuse and comorbid psychiatric disorders

Paula D Riggs, Paula D Riggs

Abstract

Recent research has identified a cluster of standardized approaches that effectively treat adolescents with substance abuse disorders. Many of these approaches share elements that may be adopted to improve outcomes in substance treatment programs. In adolescents, treatment goals should be informed by a comprehensive assessment that includes the adolescent patient's developmental history and evaluation of psychiatric comorbidity. Treatment for behavioral, psychosocial, and psychiatric problems should be integrated with substance abuse interventions. The author describes practical clinical guidelines, grounded in current research, for providing integrated treatment services. Special emphasis is given to strategies for integrating the treatment of comorbid psychiatric disorders with substance use disorders in adolescents.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2851046/bin/SPP-02-1-18-g001.jpg
Gueorgui Pinkhassov/Magnum Photos, ©2003

References

    1. Azrin NH, et al. Youth drug abuse treatment: A controlled outcome study. Journal of Child & Adolescent Substance Abuse. 1994;3(3):1–16.
    1. Birmaher B, Brent DA, Benson RS. Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37(11):1234–1238.
    1. Bukstein OG, Glancy LJ, Kaminer Y. Patterns of affective comorbidity in a clinical population of dually diagnosed adolescent substance abusers. Journal of the American Academy of Child and Adolescent Psychiatry. 1992;31(6):1041–1045.
    1. Crowley TJ, et al. Validity of structured clinical evaluations in adolescents with conduct and substance problems. Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40(3):265–273.
    1. Crowley TJ, Riggs PD. Adolescent substance use disorder with conduct disorder and comorbid conditions. In: Rahdert E, Czechowicz D, editors. Adolescent Drug Abuse: Clinical Assessment and Therapeutic Interventions. Rockville, MD: U.S. Department of Health and Human Services; 1995. pp. 49–111. NIDA Research Monograph 156. (NIH Publication No. 95-3908.)
    1. Daviss WB, et al. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40(3):307–314.
    1. Deas D, et al. Adolescents are not adults: Developmental considerations in alcohol users. Alcoholism, Clinical and Experimental Research. 2000;24(2):232–237.
    1. Deas D, Thomas SE. An overview of controlled studies of adolescent substance abuse treatment. American Journal on Addictions. 2001;10(2):178–189.
    1. Drug Strategies. Treating Teens: A Guide to Adolescent Drug Programs. Washington, DC: Drug Strategies; 2002.
    1. Emslie GJ, et al. Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41(10):1205–1215.
    1. Geller B, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37(2):171–178.
    1. Grella CE, et al. Drug treatment outcomes for adolescents with comorbid mental and substance use disorders. Journal of Nervous and Mental Disease. 2001;189(6):384–392.
    1. Haney M, et al. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology. 2001;155(2):171–179.
    1. Kaminer Y, et al. Psychotherapies for adolescent substance abusers: A pilot study. Journal of Nervous and Mental Disease. 1998;186(11):684–690.
    1. Lohman M, et al. Perceived Motivations for Treatment in Depressed, Substance-Dependent Adolescents With Conduct Disorder. College on Problems of Drug Dependence: 64th Annual Scientific Meeting; Rockville, MD: National Institute on Drug Abuse; 2002.
    1. March J, Wells K. Combining Medications and Psychotherapy. In: Leckman JF, Schill L, Charney DS, editors. Pediatric Psychopharmacology: Principles and Practice. London: Oxford University Press; 2002. pp. 426–446.
    1. Michelson D, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. American Journal of Psychiatry. 2002;159(11):1896–1901.
    1. Monti PM, et al. Motivational Enhancement for Alcohol-Involved Adolescents. In: Monti PM, Colby SM, editors. Adolescents, Alcohol, and Substance Abuse: Reaching Teens Through Brief Interventions. New York: Guilford Press; 2001. pp. 145–182.
    1. Najavits LM. Seeking Safety: A New Psychotherapy for Posttraumatic Stress Disorder and Substance Use Disorder. In: Ouimette P, Brown PJ, editors. Trauma and Substance Abuse: Causes, Consequences, and Treatment of Comorbid Disorders. Washington, DC: American Psychological Association; 2003. pp. 147–169.
    1. National Institute on Drug Abuse. Principles of Drug Addiction Treatment: A Research-Based Guide. Rockville, MD: National Institute on Drug Abuse; 1999. NIH Publication No. 99-4180.
    1. Riggs PD, Davies RD. A clinical approach to integrating treatment for adolescent depression and substance abuse. Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41(10):1253–1255.
    1. Riggs PD. Fluoxetine in drug-dependent delinquents with major depression: An open trial. Journal of Child and Adolescent Psychopharmacology. 1997;7(2):87–95.
    1. Riggs PD, et al. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37(12):1271–1278.
    1. Riggs PD, Mikulich SK, Hall S. Effects of Pemoline on ADHD, Antisocial Behaviors, and Substance Use in Adolescents With Conduct Disorder and Substance Use Disorder. College on Problems of Drug Dependence: 63rd Annual Scientific Meeting; Rockville, MD: National Institute on Drug Abuse; 2001.
    1. Riggs PD, et al. An open trial of pemoline in drug-dependent delinquents with attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 1996;35(18):1018–1024.
    1. Riggs PD, Whitmore EA. Substance Use Disorders and Disruptive Behavior Disorders. In: Hendren RL, editor. Disruptive Behavior Disorders in Children and Adolescents. Washington, DC: APA Press; 1999. pp. 133–173.
    1. Rotheram-Borus MJ, Duan N. Next generation of preventive interventions. Journal of the American Academy of Child and Adolescent Psychiatry. 2003;42(5):518–526.
    1. Rutter M, Giller H, Hagell A. Antisocial Behavior by Young People. Cambridge, UK: Cambridge University Press; 1998.
    1. Safer DJ, Zito JM, Gardner JF. Pemoline hepatotoxicity and postmarketing surveillance. Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40(6):622–629.
    1. Solhkhah R, Wilens TE. Pharmacotherapy of adolescent AOD use disorders. Alcohol Health & Research World. 1998;22(2):122–126.
    1. Tarter RE. Etiology of adolescent substance abuse: A developmental perspective. American Journal on Addictions. 2002;11(3):171–191.
    1. Teplin LA, et al. Psychiatric disorders in youth in juvenile detention. Archives of General Psychiatry. 2002;59(12):1133–1143.
    1. Tims FM, et al. Characteristics and problems of 600 adolescent cannabis abusers in outpatient treatment. Addiction. 2002;97(suppl 1):46–57.
    1. Wagner EF, et al. Innovations in adolescent substance abuse intervention. Alcoholism, Clinical and Experimental Research. 1999;23(2):236–249.
    1. Weinberg NZ, et al. Adolescent substance abuse: A review of the past 10 years. Journal of the American Academy of Child and Adolescent Psychiatry. 1998;37(3):252–261.
    1. Wilens TE, Biederman J, Spencer TJ. Case study: Adverse effects of smoking marijuana while receiving tricyclic antidepressants. Journal of the American Academy of Child and Adolescent Psychiatry. 1997;36(1):45–48.
    1. Wilens TE, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry. 2001;158(2):282–288.
    1. Winters KC, Stinchfield R, Henly GA. Convergent and predictive validity of scales measuring adolescent substance abuse. Journal of Child & Adolescent Substance Abuse. 1996;5(3):37–55.
    1. Winters KC, et al. Validity of adolescent self-report of alcohol and other drug involvement. International Journal of the Addictions. 1990;25(11A):1379–1395.
    1. Wise BK, Cuffe SP, Fischer T. Dual diagnosis and successful participation of adolescents in substance abuse treatment. Journal of Substance Abuse Treatment. 2001;21(3):161–165.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa